The first shipment of Lenacapavir, a long-acting injectable that prevents HIV with two shots a year, arrived in South Africa from the United States in early April 2026. Clinical trials showed close to 100% efficacy. The rollout, expected to begin in June 2026, prioritises adolescent girls and young women, pregnant and breastfeeding women, transgender people, sex workers, men who have sex with men, and people who inject drugs.
These are the right populations to start with. But one group repeatedly slips through the cracks: adult, employed men in mobile, male-dominated industries, who move between work sites and home, between long-term partners and casual or paid encounters. In epidemiology, they are a “bridging population”: people whose sexual networks connect higher-prevalence groups to lower-prevalence groups.
